<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02593708</url>
  </required_header>
  <id_info>
    <org_study_id>149517</org_study_id>
    <nct_id>NCT02593708</nct_id>
  </id_info>
  <brief_title>Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+</brief_title>
  <official_title>Phase I Study to Evaluate the Safety of Neratinib in Combination With Paclitaxel, Trastuzumab and Pertuzumab in Women and Men With Advanced or Metastatic HER2+ Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michelle Melisko</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label, non-randomized, dose escalation and expansion Phase Ia/b trial to evaluate the&#xD;
      safety and tolerability of the combination of neratinib plus paclitaxel, trastuzumab and&#xD;
      pertuzumab to determine the recommended Phase II/III dose of this combination.&#xD;
&#xD;
      Neratinib will be given once daily days 1-21 and should be taken orally with food. Paclitaxel&#xD;
      and trastuzumab will be given IV on days 1, 8, and 15 out of 21 day cycles. Pertuzumab will&#xD;
      be given IV every 3 weeks on day 1 out of 21-day cycles. Each cycle will be 21 days in&#xD;
      duration.&#xD;
&#xD;
      Patients will continue on treatment until disease progression or intolerable toxicity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neratinib is a potent, irreversible, small molecule panErbB inhibitor of EGFR, HER2 and HER4&#xD;
      tyrosine kinases. Its activity prevents the autophosphorylation of HER2 and thus halts the&#xD;
      downstream activation of this key proliferative pathway in tumors dependent on HER2&#xD;
      overexpression or EGFR activation. It has shown promising clinical activity in women with&#xD;
      HER2+ stage 2 and 3 breast cancer in the neoadjuvant setting (I-SPY 2 TRIAL) and in women&#xD;
      with stage 4 metastatic breast cancer, although evaluation in larger phase 3 trials is&#xD;
      required to confirm these results.&#xD;
&#xD;
      The rationale for this study is to determine the feasibility of adding neratinib to a taxane&#xD;
      based chemotherapy and the approved HER2 antagonists, trastuzumab and pertuzumab.&#xD;
&#xD;
      The study will evaluate the safety and tolerability and recommended dose of daily neratinib&#xD;
      in combination with weekly paclitaxel, trastuzumab and tri-weekly pertuzumab in patients with&#xD;
      HER2+ advanced or metastatic disease and, if successful, determine an optimal dose to move&#xD;
      into phase II/III testing of this combination in the neoadjuvant setting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    toxicity&#xD;
  </why_stopped>
  <start_date type="Actual">November 3, 2015</start_date>
  <completion_date type="Actual">July 31, 2017</completion_date>
  <primary_completion_date type="Actual">January 5, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>CTCAE v.4.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>CTCAE v.4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>RECIST v.1.1</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Cohort 0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neratinib: 80 mg, daily, oral&#xD;
Paclitaxel: 80 mg/m2, weekly, intravenously&#xD;
Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously&#xD;
Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neratinib: 120 mg, daily, oral&#xD;
Paclitaxel: 80 mg/m2, weekly, intravenously&#xD;
Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously&#xD;
Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neratinib: 160 mg, daily, oral&#xD;
Paclitaxel: 80 mg/m2, weekly, intravenously&#xD;
Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously&#xD;
Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neratinib: 200 mg, daily, oral&#xD;
Paclitaxel: 80 mg/m2, weekly, intravenously&#xD;
Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously&#xD;
Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neratinib</intervention_name>
    <arm_group_label>Cohort 0</arm_group_label>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Cohort 0</arm_group_label>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <arm_group_label>Cohort 0</arm_group_label>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <arm_group_label>Cohort 0</arm_group_label>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women and men 18 years or older with advanced solid tumor malignancy&#xD;
&#xD;
          -  Ability to understand and voluntarily sign informed consent prior to undergoing any&#xD;
             study-related assessments or procedures, as well as adhere to the study visit schedule&#xD;
             and other protocol requirements.&#xD;
&#xD;
          -  Local histologic or cytologic confirmation of HER2+ solid tumors by FISH amplification&#xD;
             or IHC (3+)&#xD;
&#xD;
          -  Patients must have received one prior approved therapy for metastatic disease and have&#xD;
             not curable options&#xD;
&#xD;
          -  For escalation: Documentation by established staging studies or clinical examination&#xD;
             to have measurable or non-measurable metastatic disease per RECIST v1.1 criteria.&#xD;
&#xD;
          -  For expansion: Documentation by established staging studies or clinical examination to&#xD;
             have measurable metastatic disease per RECIST v1.1 criteria.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.&#xD;
&#xD;
          -  Adequate organ function:&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥ 1.5 X 109/L&#xD;
&#xD;
          -  Hemoglobin (Hgb) ≥9g/dL&#xD;
&#xD;
          -  Platelets (plt) ≥ 100 x 109/L&#xD;
&#xD;
          -  Potassium within normal range, or correctable with supplements;&#xD;
&#xD;
          -  Serum calcium and magnesium within the normal range (or corrected with supplements)&#xD;
&#xD;
          -  AST and ALT ≤2.5 x Upper Limit Normal (ULN)&#xD;
&#xD;
          -  Serum total bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 x ULN, or 24-hr clearance ≥ 60ml/min&#xD;
&#xD;
          -  Serum albumin &gt; 3.0 g/dL&#xD;
&#xD;
          -  Left ventricular ejection fraction of &gt;55% (or institutional lower normal value)&#xD;
&#xD;
          -  Females of child-bearing potential (FCBP) must have negative serum pregnancy test&#xD;
             within 7 days before starting study treatment and willingness to adhere to acceptable&#xD;
             forms or birth control (a physician- approved contraceptive method: oral, injectable,&#xD;
             or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier&#xD;
             contraceptive with spermicide; or vasectomized partner)&#xD;
&#xD;
        FCBP is defined as a sexually mature women who:&#xD;
&#xD;
          -  Have not undergone a hysterectomy (the surgical removal of the uterus) or bilateral&#xD;
             oophorectomy (the surgical removal of both ovaries) or,&#xD;
&#xD;
          -  Have not been naturally postmenopausal for at least 12 consecutive months (i.e., has&#xD;
             had menses at any time during the preceding 12 consecutive months&#xD;
&#xD;
          -  Must be willing to practice abstinence or use highly effective contraception for a&#xD;
             minimum of 6 months following completion of study treatment (in addition to during&#xD;
             study therapy)&#xD;
&#xD;
          -  Male subjects with female partner of childbearing potential must agree to the use of a&#xD;
             physician-approved contraceptive method throughout the course of the study and for 3&#xD;
             months after the last dose of the investigational product.&#xD;
&#xD;
          -  Ability to take oral medications&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any significant medical condition, laboratory abnormalities, which places the subject&#xD;
             at unacceptable risk if he/she were to participate in the study.&#xD;
&#xD;
          -  Any condition that confounds the ability to interpret data from the study.&#xD;
&#xD;
          -  Patients must have recovered from side effects from prior cancer-directed therapy to&#xD;
             grade 1 or less (unless deemed not clinically significant by study investigator).&#xD;
&#xD;
          -  Symptomatic central nervous system metastases. Subjects with brain metastases that&#xD;
             have been previously treated and are stable for 4 weeks are allowed.&#xD;
&#xD;
          -  Persistent diarrhea or malabsorption ≥ NCI CTCAE grade 1, despite medical management,&#xD;
             ulcerative colitis, inflammatory bowel disease, resection of the stomach or small&#xD;
             bowel, or other disease or condition significantly affecting gastrointestinal&#xD;
             function.&#xD;
&#xD;
          -  Unstable angina, significant cardiac arrhythmia, or New York Heart Association (NYHA)&#xD;
             class III or IV congestive heart failure.&#xD;
&#xD;
          -  Grade 2 or higher neuropathy&#xD;
&#xD;
          -  Known history of: cardiac disease, heart failure or decreased left ventricular&#xD;
             ejection fraction, significant clinical arrhythmias&#xD;
&#xD;
          -  Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives&#xD;
             or 4 weeks, whichever is shorter, prior to starting study drug or who have not&#xD;
             recovered from grade 2 or higher side effects of such therapy (except alopecia).&#xD;
&#xD;
          -  Major surgery ≤ 2 weeks prior to starting a study drug or who have not recovered from&#xD;
             side effects of such therapy.&#xD;
&#xD;
          -  Known allergic reaction to neratinib, pertuzumab, trastuzumab, paclitaxel, or any of&#xD;
             their components.&#xD;
&#xD;
          -  Women who are pregnant or breast-feeding.&#xD;
&#xD;
          -  Known active Human Immunodeficiency Virus (HIV) infection, Hepatitis B or C.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>October 30, 2015</study_first_submitted>
  <study_first_submitted_qc>October 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2015</study_first_posted>
  <last_update_submitted>November 13, 2017</last_update_submitted>
  <last_update_submitted_qc>November 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Michelle Melisko</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>HER2+</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

